Immune-toxicity model and efficacy biomarkers enable precise NSCLC immunotherapy stratification
A new analysis of the phase 3 ORIENT-11 trial suggests that the future of lung-cancer immunotherapy may depend not only ...
A new analysis of the phase 3 ORIENT-11 trial suggests that the future of lung-cancer immunotherapy may depend not only ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine